Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2023. Read More.
Open Access Percentage
61%
Total
Publications
809
Total Open
Publications
492
Total
Citations
75K
Open Access
Percentage
61%
Total
Publications
809
Total Open
Publications
492
Total
Citations
75K
Breakdown
Publisher Open
17%
Both
34%
Other Platform Open
10%
Closed
39%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 29%
118
Hybrid 34%
138
No Guarantees 37%
153
Other Platform Open
Domain 83%
293
Institution 23%
83
Preprint 14%
50
Other Internet 8%
27
Public 7%
26
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 291 |
Europe PMC | Domain | 166 |
bioRxiv | Preprint | 24 |
University College London - UCL Discovery | Institution | 19 |
Semantic Scholar | Public | 19 |
medRxiv | Preprint | 14 |
Massachusetts Institute of Technology - DSpace@MIT | Institution | 14 |
DOI | Other Internet | 12 |
Research Square | Preprint | 11 |
Figshare | Public | 11 |